PD-L1 IHC 22C3 pharmDx: Analytical validation on cervical cancer specimens

被引：0
|
作者：
Musser, J. [1 ]
Evans, T. [1 ]
Posch, A. [1 ]
Vasquez, J. [1 ]
Tabuena-Frolli, S. [1 ]
Apostolaki, A. [1 ]
Kulangara, K. [1 ]
机构：
[1] Agilent Technol, Santa Clara, CA USA
来源：
VIRCHOWS ARCHIV | 2022年 / 481卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
PS-08-011
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 50 条
  • [31] Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC
    Sughayer, Maher A.
    Alnaimy, Farah
    Alsughayer, Anas M.
    Qamhia, Naim
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2019, 27 (09) : 663 - 666
  • [32] PD-L1 antigen stability using PD-L1 IHC pharmDx on human cancer tissues
    Kalpakoff, Megan
    Olander, Emily
    Jones, Kelci
    Hund, Stephanie
    Evans, Tiffany
    Barreto, Joseph
    Moquin, Deanna
    Toland, Grant
    Tabuena-Frolli, Siena
    Kersch, Kristopher
    Kulangara, Karina
    Musser, Jeanette
    CANCER RESEARCH, 2024, 84 (06)
  • [33] Simulated digital gastric cancer endoscopic biopsies and surgical resections stained with PD-L1 IHC 22C3 pharmDx present similar PD-L1 expression when scored using combined positive score
    Monaco, D.
    Quiroz, J.
    Olander, E.
    Kulangara, K.
    Hund, S.
    Peltz, L.
    Manna, E.
    Tabuena-Frolli, S.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S103 - S103
  • [34] A Comparative Study of the PD-L1 IHC 22C3 and 28-8 Assays on Lung Cancer Samples
    Krigsfeld, G. S.
    Zerba, K.
    Novotny, J., Jr.
    Chizhevsky, V.
    Ragheb, J. W.
    White, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (01): : 236 - 237
  • [35] USE OF THE COMBINED POSITIVE SCORE (CPS) WITH THE COMPANION DIAGNOSTIC PD-L1 IHC 22C3 PHARMDX PROVIDES PRECISE EVALUATION OF PD-L1 EXPRESSION ACROSS MULTIPLE TUMOR INDICATIONS AND CUTOFFS
    Ponce, Francisco
    Hund, Stephanie
    Peltz, Lindsay
    La Placa, Chris
    Vilardo, Monika
    Watts, Brittany
    Tabuena-Frolli, Siena
    Toland, Grant
    Posch, Alex
    Milo, Jay
    Kulangara, Karina
    Apostolaki, Angeliki
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A68 - A68
  • [36] PD-L1 IHC 22C3 pharmDx helps determine first-line pembrolizumab eligibility in head and neck squamous cell carcinoma patients
    La Placa, C.
    Watts, B.
    Vilardo, M.
    Polewski, M.
    Tabuena-Frolli, S.
    Jansson, M.
    Juco, J.
    Emancipator, K.
    Jin, F.
    Gumuscu, B.
    Ge, J.
    Kulangara, K.
    VIRCHOWS ARCHIV, 2020, 477 : S79 - S79
  • [37] HIGH SCORING PRECISION DEMONSTRATED IN MULTIPLE TUMOR INDICATIONS STAINED WITH PD-L1 IHC 22C3 PHARMDX USED IN CONJUNCTION WITH COMBINED POSITIVE SCORE
    Hand, Julia
    Ponce, Francisco
    Hund, Stephanie
    Peltz, Lindsay
    Adams, Micki
    Moquin, Deanna
    Kalpakoff, Megan
    Tabuena-Frolli, Siena
    Milo, Jay
    Apostolaki, Angeliki
    Kulangara, Karina
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A76 - A76
  • [38] Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263
    Fujimoto, Daichi
    Yamashita, Daisuke
    Fukuoka, Junya
    Kitamura, Yuka
    Hosoya, Kazutaka
    Kawachi, Hayato
    Sato, Yuki
    Nagata, Kazuma
    Nakagawa, Atsushi
    Tachikawa, Ryo
    Date, Naoki
    Sakanoue, Ichiro
    Hamakawa, Hiroshi
    Takahashi, Yutaka
    Tomii, Keisuke
    ANTICANCER RESEARCH, 2018, 38 (12) : 6891 - 6895
  • [39] Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types
    Krigsfeld, Gabriel S.
    Prince, Emily A.
    Pratt, James
    Chizhevsky, Vladislav
    Ragheb, Josette William
    Novotny, James, Jr.
    Huron, David
    JOURNAL OF CLINICAL PATHOLOGY, 2020, 73 (10) : 656 - 664
  • [40] Analysis of Real-World PD-L1 Testing and PD-L1 IHC 28-8 and 22C3 Assay Concordance in Patients with Breast Cancer
    Prince, Emily
    Pratt, James
    Novotny, James
    Chizhevsky, Vladislav
    Ragheb, Josette William
    Huron, David
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 238 - 239
12345